SKyvec™ AAV Manufacturing for Advanced Therapies

We support AAV production from early research through 500 L or 1,000 L bioreactors, ensuring seamless scale-up from preclinical development through CGMP commercial AAV manufacturing.

Yes. We provide fully customized AAV production services for unique serotypes, transgenes, or project-specific requirements. 

Our optimized suspension platforms, robust process development, and CGMP readiness ensure reproducible titers, high vector integrity, and consistent results across all AAV vector production batches.

Yes. We offer off-the-shelf plasmids that reduce costs, remove licensing concerns, and enable rapid project initiation for both platform and custom AAV CDMO services.

Our AAV manufacturing expertise spans multiple serotypes, from AAV1 to AAV9, AAVrh74, AAV11, and novel capsids, and is optimized for efficiency, scalability, and reproducibility across a variety of therapeutic applications.

Optimized upstream and downstream workflows enable high titers, 25-70% yields, and up to 92% full particles, providing cost-efficient and reliable AAV vector production.

Cost reduction is approached through intelligent design rather than scale alone. By simplifying plasmid systems and improving process efficiency, production becomes more predictable and economically viable. 

Reducing plasmid complexity while increasing output fundamentally shifts the cost structure—delivering more effective vector per batch while shortening timelines and reducing operational burden. 

Yes. With our platform and CGMP experience, programs can progress from gene to clinic in as little as 8 months, accelerating patient access.

Scalability is built into process design from the outset, with development conducted at scales up to 200 L to mirror manufacturing conditions and enable a smooth transition into GMP production. Consistent output is maintained across scales to minimize variability during tech transfer, supported by a dedicated MSAT team that ensures process control, knowledge transfer, and reliable scale-up from 200 L through 500 L and 1,000 L bioreactors.

We deliver AAV CDMO services with regulatory-ready systems, QC expertise, and a track record of CGMP batches that support IND and BLA submissions worldwide.

Our AAV vector production supports a wide range of programs, including rare diseases, gene replacement therapies, and systemic indications where high-quality vectors are essential.

Risk is mitigated through process designs that maintain consistent titers and performance across scales, combined with robust control of critical process parameters and cell health. Early integration of CQAs, scalable platform technologies, and strong analytical support ensure predictable outcomes from development through GMP manufacturing.

We offer off-the-shelf plasmids that reduce costs, eliminate licensing concerns, and allow rapid project start-up, providing flexibility for both platform and custom programs.

Yes, in addition to suspension capabilities, an adherent AAV solution provides an alternative route to production.